Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of AKB-6548 on QT Interval in Healthy Volunteers
NCT02062203Phase 1Completed
- Sponsor
- Akebia Therapeutics
- Start
- Jan 2014
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vadadustat in anemia of chronic kidney disease (CKD-A) (4 arms), sponsored by Akebia Therapeutics. Primary endpoint: Placebo-corrected change-from-baseline QTcF at 24 hours. Started Jan 2014; status: completed.
02
Drugs
vadadustat
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT02062203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02062203.